Welcome to our dedicated page for Beam Therapeutics SEC filings (Ticker: BEAM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Beam Therapeutics Inc. (BEAM) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a Nasdaq-listed biotechnology issuer. Beam files reports and current reports with the U.S. Securities and Exchange Commission that describe its financial condition, clinical development progress and material corporate events related to its precision genetic medicines platform.
Investors can review Form 8-K filings in which Beam reports items such as quarterly financial results and significant transactions. For example, the company has used Form 8-K to furnish press releases announcing results for quarters ended June 30 and September 30, and to disclose an Agreement and Plan of Merger under which it acquired an early-stage life sciences company in exchange for upfront shares and potential milestone-based consideration.
In addition to 8-Ks, Beam’s periodic reports on Form 10-K and Form 10-Q (accessible via EDGAR and summarized on this page when available) typically include information on its base editing platform, programs such as risto-cel (formerly BEAM-101), BEAM-302 and BEAM-301, risk factors, liquidity and capital resources. These filings also describe regulatory designations, clinical trial status and collaboration arrangements that are important for understanding the company’s development-stage business.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly identify disclosures on topics like clinical milestones, cash runway, collaboration agreements and equity issuances. Real-time updates from EDGAR ensure that new Beam filings, including any future Forms 4 reporting insider transactions or proxy statements on executive compensation and governance, are surfaced promptly.
By combining official SEC documents with AI-generated overviews, this page helps investors and researchers analyze Beam’s regulatory history, financial reporting and material events that influence the BEAM stock narrative.
John M. Evans, Beam Therapeutics Inc. CEO and director, reported option exercises and sales in early October 2025 under a Rule 10b5-1 plan. On 10/01/2025 and 10/02/2025 he exercised two stock option tranches at a $0.67 strike for 25,000 shares each and sold corresponding blocks of 25,000 shares on each date. The sales were executed as multiple transactions at weighted average prices of approximately $24.5062 (range $24.14–$24.92) and $24.6267 (range $24.22–$25.05). Following the reported acquisitions, Mr. Evans beneficially owned 1,011,667 shares directly and 103,000 shares indirectly via the John M. Evans, III 2018 Irrevocable Trust. The Form 4 notes the option grants dated 05/08/2018 with portions still exercisable and expiring on 05/08/2028, and that the trades were made pursuant to a trading plan adopted on 05/16/2025.
An insider filing under Rule 144 discloses the proposed sale of 25,000 common shares of Beam Therapeutics (BEAM). The shares were acquired via a stock option exercise and paid in cash on 10/02/2025. The sale is to be executed through Morgan Stanley Smith Barney LLC with an indicated aggregate market value of $615,667.50 and the issuer's shares outstanding listed as 100,557,094. The filing also reports a prior sale of 25,000 shares on 10/01/2025 that generated $612,655.00 in gross proceeds. The filer certifies they are not aware of undisclosed material adverse information about the issuer.
Beam Therapeutics (BEAM) filed a Rule 144 notice disclosing a proposed sale of 25,000 common shares through Morgan Stanley Smith Barney LLC on the NASDAQ with an aggregate market value of $612,655.00. The filing reports 101,162,026 shares outstanding for the issuer.
The securities were acquired and paid for on 10/01/2025 by a stock option exercise from the issuer, with payment in cash. The filer reports no securities sold in the past three months and includes the standard representation that the seller is not aware of undisclosed material adverse information.
Filing: Amendment No. 9 to Schedule 13G filed for BEAM THERAPEUTICS INC (CUSIP 07373V105) reporting a beneficial ownership position.
Key facts: FMR LLC and Abigail P. Johnson report aggregate beneficial ownership of 15,083,498.08 shares (15.0%). FMR LLC reports sole voting power of 15,073,316 and sole dispositive power of 15,083,498.08; shared powers are 0. Abigail P. Johnson reports sole dispositive power of 15,083,498.08 and no voting power. The "Date of Event Which Requires Filing" is 06/30/2025 and the signature date is 08/05/2025. Item 10 certifies the securities were not acquired to change or influence control. Exhibits referenced: Exhibit 99 (13d-1(k)(1) agreement) and Exhibit 24 (power of attorney).
Report type: Current Report on Form 8-K dated August 5, 2025 by Beam Therapeutics Inc. (BEAM).
On August 5, 2025 the Company issued a press release announcing its financial results for the quarter ended June 30, 2025. The press release is furnished as Exhibit 99.1 and is incorporated by reference into Item 2.02. The filing states that the information and Exhibit 99.1 are being furnished (not "filed") for purposes of the Exchange Act and are not subject to Section 18 liability except by specific reference.
Corporate details: Beam Therapeutics Inc., Delaware, principal office 238 Main Street, Cambridge, MA 02142; common stock trades as BEAM on Nasdaq Global Select Market. Form signed by John Evans, Chief Executive Officer.